WuXi Biologics announces solid 2024 results amid headwinds
WuXi Biologics (2269.HK) reported a 9.6% year-on-year increase in revenue to RMB 18.68 billion for 2024, with non-COVID revenue up 13.1%. Gross profit rose by 12.1% to RMB 7.65 billion. Net profit grew by 10.5% to RMB 3.95 billion. The company added 151 new integrated projects, bringing the total to 817. Late-phase and commercial manufacturing businesses also experienced growth. Backlog reached US$18.5 billion. Basic earnings per share remained flat at RMB 0.82. The board did not recommend a final dividend. The company highlights continuous investment in capabilities and capacity, coupled with collaborations as key to future growth.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when WuXi Biologics (Cayman) Inc publishes news
Free account required • Unsubscribe anytime